The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Fate Therapeutics, Inc(NASDAQ:FATE)


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...
Website: http://www.fatetherapeutics.com
Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology
Fate Therapeutics Days Payable Outstanding ttm (DPO)
Fate Therapeutics Days Receivable Outstanding ttm (DSO)
Fate Therapeutics Op Cashflow Per Share ttm
Fate Therapeutics Free Cashflow Per Share ttm
Fate Therapeutics Cash Per Share ttm
Fate Therapeutics P/S ratio ttm
Fate Therapeutics (GAAP) P/E ratio ttm
Fate Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.